TMEM161BP1: A Transmembrane Protein Target for Therapeutic Intervention

Target Name: TMEM161BP1

NCBI ID: G646360

TMEM161BP1

Other Name(s): transmembrane protein 161B pseudogene 1 | Transmembrane protein 161B pseudogene 1

TMEM161BP1: A Transmembrane Protein Target for Therapeutic Intervention

TMEM161BP1, also known as transmembrane protein 161B pseudogene 1, is a gene that encodes a protein involved in various cellular processes. The protein has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In this article, we will provide an overview of TMEM161BP1, its potential drug target status, and its clinical implications.

Synonyms and Background

TMEM161BP1 is a member of the transmembrane protein family, which includes proteins involved in various cellular processes, including cell signaling, intracellular transport, and tissue structure. TMEM161BP1 is characterized by a unique topology, where the protein forms a transmembrane domain and a cytoplasmic domain. The cytoplasmic domain is involved in protein-protein interactions and may play a role in the protein's localization and stability.

TMEM161BP1 has been identified in various organisms, including humans, using various techniques, such as transcriptomics, genomics, and biochemical assays. The protein has been shown to be involved in various cellular processes, including cell signaling, cell division, and tissue structure. TMEM161BP1 has also been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

Potential Drug Target and Biomarker

TMEM161BP1 has been identified as a potential drug target due to its unique structure and various functions. The protein has been shown to play a role in various cellular processes, including cell signaling and tissue structure. This suggests that TMEM161BP1 may be a useful target for therapeutic intervention in diseases associated with these processes.

In addition to its potential drug target status, TMEM161BP1 has also been identified as a potential biomarker for various diseases. The protein has been shown to be involved in various cellular processes, including cell signaling and tissue structure. This suggests that TMEM161BP1 may be a useful biomarker for diseases associated with these processes.

Clinical Implications

The potential drug target and biomarker status of TMEM161BP1 makes it an attractive target for therapeutic intervention in various diseases. The protein has been shown to be involved in various cellular processes, including cell signaling and tissue structure, which suggests that it may be a useful target for diseases associated with these processes.

In addition to its potential drug target and biomarker status, TMEM161BP1 may also have implications for cancer diagnosis and treatment. TMEM161BP1 has been shown to be involved in various cellular processes, including cell signaling and tissue structure, which suggests that it may be a useful target for cancer therapies that target these processes.

Conclusion

TMEM161BP1 is a transmembrane protein that has been identified in various organisms as having potential drug target and biomarker status. The protein has been shown to play a role in various cellular processes, including cell signaling and tissue structure, which suggests that it may be a useful target for therapeutic intervention in various diseases. Further research is needed to determine the full potential of TMEM161BP1 as a drug target and biomarker.

Protein Name: Transmembrane Protein 161B Pseudogene 1

The "TMEM161BP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM161BP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets